Collaboration between the pharmaceutical industry and Healthcare Professionals (HCPs) or Healthcare Organizations (HCOs) or Patient Organizations (PO) benefit patients. These relationships have delivered numerous breakthrough medicines and have helped improve the way many diseases are treated and managed.
Our work together includes a range of activities, from clinical research to sharing best clinical practices. As part of these collaborations, Novartis may provide payments or other “transfers of value” to healthcare professionals and organizations to compensate them for their time, expertise, and services.
Bringing greater transparency to this already well-regulated relationship helps build understanding of these collaborations and address public concerns about interactions between the medical community and the pharmaceutical industry. We believe that openly communicating payments helps foster trust with patients, healthcare professionals, government officials and the public. It also supports our broader commitment to transparency, data sharing, and high ethical business standards.
Novartis has long been dedicated to improving clinical trial data transparency and discloses relationships with patient organizations.
In several countries, we publish information about payments and other transfer of values to Healthcare Professionals, Healthcare Organizations and Patient Organizations in line with local laws, regulations, and industry codes.
About our reporting practices
Europe
Across Europe, Novartis annually discloses payments and other transfers of value in line with the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code and its local transpositions. The EFPIA Disclosure Code 2026 Self-Certification Letter (PDF 0.1 MB) signed by Patrick Horber, Novartis President, International, confirms the application of the principles of the EFPIA Disclosure Code. The letter from previous year is available here (PDF 0.4 MB).
United States
Under the Sunshine Act, Novartis is required each year to submit data to the Centers for Medicare and Medicaid Services (CMS) Open Payments Program (commonly known as the Sunshine Act) as an applicable manufacturer.
CMS collects information about certain payments and other transfers of value from applicable manufacturers and group purchasing organizations (GPOs) to physicians and teaching hospitals. Open Payments is the federally run transparency program that collects information about these financial relationships and makes it available to the public annually through the CMS Open Payments website.
Read more about our Payments to Healthcare Professionals in the United States.
Rest of the world
In addition to the EFPIA countries and the United States, we publicly disclose transfers of value in Australia, Brazil, Colombia, Canada, Israel, Japan and New Zealand.
In India, Indonesia, Philippines and Saudi Arabia, transfers of value are reported to the government.
In South Korea and Turkey, transfers of value are collected and shared with the Ministry of Health upon request.